Navigation Links
Oncolytics Biotech Inc. Announces Details of 2008 Annual Shareholder Meeting
Date:5/5/2008

CALGARY, May 5 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that its 2008 Annual and Special Meeting of the Shareholders will be held on Wednesday, May 7, 2008 at 9:00 a.m. (ET) at the Yale Club of New York City, 50 Vanderbilt Ave, New York.

Following the business portion of the meeting, Dr. Brad Thompson, President and CEO of Oncolytics, will discuss recent progress in developing REOLYSIN(R) as a potential cancer therapeutic.

A live audio webcast of the presentation will begin at approximately 9:15 a.m. (ET) at: http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=2266660 or on the company's website at http://www.oncolyticsbiotech.com. It is recommended that listeners log on 15 minutes in advance of the presentation to register and download any necessary software.

An audio replay will be accessible following the presentation at http://www.oncolyticsbiotech.com.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com

The presentation time is subject to change. This release and the presentation related thereto contain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control and which may cause actual results, performanc
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent ... viruses is the Epstein Barr Virus (EBV), and one of ... a chronic inflammatory disease that destroys the body’s joints. As ... have high concentrations of EBV DNA in their bodies (1). ...
(Date:1/15/2014)... 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today announced ... a leading Russian pharmaceutical company, to develop and commercialize ... Federation , Turkey and ... a novel antibiotic for the treatment of bacterial infections ...
(Date:1/14/2014)... 14, 2014 As pet owners drew up their lists of ... wrote: "Take better care of my furry companion." Nowadays there are ... top-brand carrying cases to take the little canine or feline darlings ... compelled to buy some pricey toys at the pet store. But ...
(Date:1/14/2014)... 2014 In recent years, growing suspicion ... in product development and promotion has led to unprecedented ... fueled by concerns about the insidious impact of commercialization ... spectacular fines to the world’s biggest pharmas for illegal ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... Managing RA: The Strong Woman,s Approach , ... living with rheumatoid arthritis (RA), launched today at HealthyWomen.org.  There ... two to three times more likely to develop the disease ... provides practical solutions and exercise advice specifically designed to address ...
... the University of Massachusetts Amherst report that for the ... of preparing ordered magnetic materials than ever before, by ... The innovative process allows them to create ... more effectively and with fewer steps than more complicated ...
... Pa., Sept. 27, 2011 Renmatix , ... the Plantrose™ process, the company,s commercial approach to ... to non-food derived low-cost industrial sugars, the foundation ... dramatic shift from petroleum-based fuels and chemicals to ...
Cached Biology Technology:The Strong Woman's Approach to Managing Rheumatoid Arthritis 2The Strong Woman's Approach to Managing Rheumatoid Arthritis 3The Strong Woman's Approach to Managing Rheumatoid Arthritis 4New nanostructure-based process will streamline production of magnetic materials 2New nanostructure-based process will streamline production of magnetic materials 3Renmatix Reveals Supercritical Hydrolysis as Lowest-Cost Pathway to Cellulosic Sugar 2Renmatix Reveals Supercritical Hydrolysis as Lowest-Cost Pathway to Cellulosic Sugar 3
(Date:7/9/2014)... penguins shows that the population is 3.79 million ... estimated. Adlie penguins have long been considered a ... effects of climate change and fishing in the ... researchers from Stony Brook University and University of ... regular monitoring of Adlie penguins across their entire ...
(Date:7/9/2014)... is one of the amphibians with the highest distribution ... areas of water where it comes into contact with ... Research carried out by the Spaniard Germn Orizaola from ... of these frogs have developed a defensive response to ... larger bodies if they co-exist with the crayfish. , ...
(Date:7/9/2014)... and increase the survival rate of naturally aged ... of Pharmaceutical Sciences, Southwest University, China performed an ... with low dose of levothyroxine for 3 consecutive ... an obvious improvement in cognitive and an increased ... underlying mechanism was demonstrated that levothyroxine treatment can ...
Breaking Biology News(10 mins):New study finds that Adélie penguin population is on the rise 2New study finds that Adélie penguin population is on the rise 3Frogs have developed rapid defences against the red swamp crayfish 2Frogs have developed rapid defences against the red swamp crayfish 3
... deaths linked to those products are fostering new concerns ... the cover story in the current edition of Chemical ... the American Chemical Society, the world,s largest scientific society. ... have surfaced with increasing frequency in recent years about deaths ...
... athlete speeds along the cross-country ski run. Things are looking good ... a new personal best time. However, whether or not he finishes ... tight timings everything must be right, including the conditions on the ... and the optimally adapted custom-fit skis. In contrast to Olympic skiing ...
... to support the idea that celiac disease is increasing in ... more gluten. That,s the conclusion of an article in the ... Donald D. Kasarda cites evidence that the incidence of celiac ... Some estimates indicate that the disease is 4 times more ...
Cached Biology News:Optimized custom-made ski sledges 2Optimized custom-made ski sledges 3
... its effects by binding ... a disulfide-linked heterotetrameric protein ... subunits and two Beta ... following configuration: Beta-Alpha-Alpha-Beta. ...
Excellent safety and durability., Remote control can be easily operated in your hand., Constant voltage control with 2 sets of terminals., Precise and durable circuit design. ...
... Dye runs faster than Bromophenol blue,or ... gels.,Orange G dye migrates with DNA ... migration at this size,prevents the obscuring ... the front of DNA migration.,The Orange ...
... Polyclonal Antibody Description: ... polyclonal antibody. Detects 70 kDa YAP ... blotting and immunohistochemistry. ... Storage: -20C ...
Biology Products: